

MAY 25 2005

AMGEN

Amgen Inc.
One Amgen Center Drive
Law Department, MS 27-4-A
Thousand Oaks, CA 91320-1799
Phone: 805.447.1000
Fax: 805.499.8011

Facsimile Cover Sheet

Date: May 25, 2005

To: Richard L. Raymond

Company: Primary Examiner, United States Patent & Trademark Office

Phone: 571-272-0673

Facsimile: 703-872-9306

From: Joseph W. Bullock

Telephone: (805) 447-7966

Facsimile (805) 499-8011

Copies to:

Number of pages: 4 pages transmitted including facsimile cover sheet. If all pages are not received, please contact Tonya Torraca at (805) 447-2038.

Comments: Please find attached a Letter of Terminal Disclaimer for the application identified below:

Chen et al., Serial No. 10/046,681, Filed January 10, 2002, SUBSTITUTED ALKYLAMINE
DERIVATIVES AND METHODS OF USE, Docket No. A-733A.

RECEIVED
MAY 26 2005
OIPE/JCWS

THIS TRANSMISSION MAY CONTAIN CONFIDENTIAL AND / OR PRIVILEGED INFORMATION INTENDED SOLELY FOR THE ADDRESSEE. IF YOU ARE NOT THE ADDRESSEE, ANY DISCLOSURE OR USE OF THIS INFORMATION BY YOU IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS FACSIMILE IN ERROR, PLEASE NOTIFY US IMMEDIATELY.

Law Fax Cover 8011 Ver. 1 08/04

MAY 25 2005

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Chen et al.

Serial No.: 10/046,681

Group Art Unit No.: 1624

Filed: January 10, 2002

Examiner: Richard L. Raymond

For: SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE

Docket No.: A-733A

LETTER TRANSMITTING TERMINAL DISCLAIMER


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith is a Terminal Disclaimer.

Please charge \$110.00 (37 CFR 1.20 (d)) to Deposit Account No. 01-0519 in the name of Amgen Inc. The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 01-0519. An original and one copy of this paper are enclosed.

Respectfully submitted,



Joseph W. Bullock
Attorney/Agent for Applicant(s)
Registration No.: 37,103
Phone: (805) 447-7966
Date: May 25, 2005


Please send all future correspondence to:

US Patent Operations/JWB
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below:

May 25, 2005
Date



MAY 25 2005

PATENT APPLICATIONIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Chen et al.
Serial No.: 10/046,681 Group Art Unit No.: 1624
Filed: January 10, 2002 Examiner: Richard L. Raymond
For: SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE
Docket No.: A-733A

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE
PATENTING REJECTION OVER A PENDING APPLICATION

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Petitioner, Amgen Inc., is the owner of the entire interest in the instant application.

Petitioner hereby disclaims the terminal part of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term as presently shortened by any terminal disclaimer of U.S. Patent No. 6,878,714, and hereby agrees that any patent so granted on said above-identified application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent No. 6,878,714, this agreement to run with any patent granted on said above-identified application and to be binding upon the grantee, its successors, or assigns.

Petitioner does not disclaim any terminal part of any patent granted on said above-identified application that would extend to the full statutory term as presently shortened by any terminal disclaimer of U.S. Patent No. 6,878,714 in the event that said U.S. Patent No. 6,878,714 later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321(a), has all claims canceled by a reexamination certificate, is reissued, or is otherwise terminated prior to the expiration of its statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above.

Copies of the assignment documents in the chain of title from the original owner to assignee are attached, and were recorded in the Patent and Trademark Office at reel Q12505 and frame 0096.

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being facsimile transmitted to the United States Patent and Trademark Office on the date shown below:

May 25, 2005
Date



PATENT APPLICATION

The undersigned has reviewed the attached assignment documents and certifies that, to the best of the undersigned's knowledge and belief, title is in the assignee identified above.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,



Joseph W. Bullock
Attorney/Agent for Applicant(s)
Registration No.: 37,103
Phone: (805) 447-7966
Date: May 25, 2005

Please send all future correspondence to:

US Patent Operations/JWB
Dept. 4300, M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799